First patient vaccinated in large melanoma study

Recently, the Radboudumc started an experimental treatment with a vaccine that reduces the risk of recurrence of skin cancer. In January, the first patient was vaccinated!

Jolanda de Vries and her team obtained a budget of 20 million euros from the national basic health insurance to introduce the experimental treatment. The therapy activates the immune system and is intended for melanoma patients of whom recently the lymph nodes with cancer metastases have been removed. The study will last until 2021 and the treatment will be offered in Nijmegen, Amsterdam, Rotterdam and Zwolle.‚Äč